BrainChild Bio Masterminds $116M Series A to Advance CAR-T Therapy for Pediatric Brain Cancer

Seattle biotech startup BrainChild Bio has raised $116M in Series A financing from Seattle Children’s and new investor WRF Capital, to advance its pivotal Phase 2 clinical trial of an experimental CAR-T cell therapy being developed to treat diffuse intrinsic pontine glioma (DIPG), a deadly form of childhood brain cancer.